Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Gadofosveset Trisodium · Ablavar, MS-32520

Small molecule · developed by Lantheus Medcl

Approved FDA, Dec 2008
LNTH Developer

What is Gadofosveset Trisodium?

Gadofosveset trisodium is a gadolinium-based contrast agent that binds reversibly to serum albumin, which prolongs its intravascular residence time and increases blood signal on magnetic resonance angiography. It is used to visualize blood vessels and has been studied in pulmonary embolism.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ablavar, MS-32520, Gadofosveset Triodium
Drug type
Small molecule
Therapy area
Cardiovascular
Developer
Lantheus Medcl (LNTH)
FDA status
Approved as Ablavar (December 22, 2008), NDA021711 · FDA label
UNII
XM33Q67UVH

✅ FDA-approved uses

From the indications section of the FDA label (version of Jan 9, 2017). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Pulmonary Embolism

More from Lantheus Medcl

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LNTH page.

Follow LNTH, the company behind Gadofosveset Trisodium

See LNTH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LNTH catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.